- Home
- DXR vs CPIX Comparison
DXR vs CPIX Comparison
Compare DXR & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- CPIX
- Stock Information
- Founded
- DXR 1970
- CPIX 1999
- Country
- DXR United States
- CPIX United States
- Employees
- DXR N/A
- CPIX N/A
- Industry
- DXR Medical/Dental Instruments
- CPIX Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- CPIX Health Care
- Exchange
- DXR Nasdaq
- CPIX Nasdaq
- Market Cap
- DXR 46.9M
- CPIX 46.2M
- IPO Year
- DXR N/A
- CPIX 2009
- Fundamental
- Price
- DXR $13.50
- CPIX $3.50
- Analyst Decision
- DXR Strong Buy
- CPIX
- Analyst Count
- DXR 1
- CPIX 0
- Target Price
- DXR $25.00
- CPIX N/A
- AVG Volume (30 Days)
- DXR 5.1K
- CPIX 24.8K
- Earning Date
- DXR 01-01-0001
- CPIX 11-06-2025
- Dividend Yield
- DXR N/A
- CPIX N/A
- EPS Growth
- DXR 3.46
- CPIX N/A
- EPS
- DXR 0.36
- CPIX N/A
- Revenue
- DXR $66,306.00
- CPIX $42,071,813.00
- Revenue This Year
- DXR N/A
- CPIX N/A
- Revenue Next Year
- DXR N/A
- CPIX N/A
- P/E Ratio
- DXR $38.30
- CPIX N/A
- Revenue Growth
- DXR N/A
- CPIX 11.34
- 52 Week Low
- DXR $6.55
- CPIX $1.04
- 52 Week High
- DXR $14.00
- CPIX $7.25
- Technical
- Relative Strength Index (RSI)
- DXR 66.65
- CPIX 58.65
- Support Level
- DXR $13.39
- CPIX $3.05
- Resistance Level
- DXR $14.00
- CPIX $3.33
- Average True Range (ATR)
- DXR 0.50
- CPIX 0.21
- MACD
- DXR 0.13
- CPIX 0.03
- Stochastic Oscillator
- DXR 80.93
- CPIX 91.55
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.